Christiansen, E. et al. (2013) Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. Journal of Medicinal Chemistry, 56(3), pp. 982-992. (doi: 10.1021/jm301470a)
Full text not currently available from Enlighten.
Abstract
The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucosestimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure−activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Hudson, Dr Brian and Milligan, Professor Graeme |
Authors: | Christiansen, E., Due-Hansen, M.E., Urban, C., Grundmann, M., Schmidt, J., Hansen, S.V.F., Hudson, B.D., Zaibi, M., Markussen, S.B., Hagesaether, E., Milligan, G., Cawthorne, M.A., Kostenis, E., Kassack, M.U., and Ulven, T. |
College/School: | College of Medical Veterinary and Life Sciences > School of Molecular Biosciences |
Journal Name: | Journal of Medicinal Chemistry |
Publisher: | American Chemical Society |
ISSN: | 0022-2623 |
University Staff: Request a correction | Enlighten Editors: Update this record